High-class research is key
Intensive research activities and state-of-the-art technologies form the backbone of Boehringer Ingelheim’s animal health business. In our global R&D centres scientists are working on innovative solutions to serve our customers best. Unmet medical needs are their challenges and it is their ambition to find innovative and effective solutions. The number of newly emerging diseases in an increasingly global community and climate change are expected to increase. Timely provision of vaccines in response to these diseases will be a key factor for keeping animals and subsequently humans healthy.
As a research-driven company with more than 3500 employees worldwide, it continuously invests more than 11 % of its revenues in R&D. This is one of the highest rates in the industry. Boehringer Ingelheim Animal Health is driven by the wish to improve animal welfare as an integral part of a healthy future for mankind.
Numerous partnerships with academic institutions all around the world and Boehringer Ingelheim’s R&D in Human Pharmaceuticals provide a unique and effective scientific environment. International teams are working together in the worldwide network to bring innovative solutions to the marketplace for the benefit of our customers.
